Healio Gastroenterology Current Issue
The following articles appeared in the print edition of Healio Gastroenterology.
Table of Contents
- Evidence-based dietary strategies critical component of IBD care Kelly Issokson, MS, RD
-
- Personalized dietary plans increase compliance, improve outcomes in GERD Emily Haller, MS, RDN
- GI dietitians critical to celiac disease, gluten-sensitivity management Jessica Lebovits, RD, CDN
- Low-FODMAP diet for IBS ‘not intuitive,’ must be taught by a GI dietitian Beth Rosen, MS, RD, CDN
- Expert dietitians play ‘powerful role’ in the care of GI patients Kate Scarlata, MPH, RDN
- Beyond Celiac joins the #ShineALightOnCeliac campaign for celiac disease awareness Kate Young
- Cell-free DNA blood test ‘poised to have significant impact’ on CRC screening Monica Stonehill
- ChatGPT fails ACG tests, ‘should be validated’ before use in gastroenterology Monica Stonehill
- Court upholds Bausch Health victory in Xifaxan fight; Norwich generic blocked until 2029 Robert Stott
-
- FDA approves Linzess as first treatment for pediatric functional constipation
- FDA approves Rinvoq as first oral therapy for moderate to severe Crohn’s disease
- ‘High-tech, high-touch’ patient care key to improving chronic conditions like Crohn’s Antonio Perez, MD, MBA, FACC, FHFSA
- Hormone replacement therapy increases risk for GI cancers in postmenopausal women Kate Burba
- Intercept pivots away from NASH following second FDA rejection for obeticholic acid
- Nearly 40% of posts about cirrhosis, liver disease on TikTok contain misinformation Monica Stonehill
- Offering a blood test as a secondary option boosts CRC screening by nearly twofold Kate Burba
- Pegozafermin improves fibrosis, shows promise as ‘mainstay treatment’ for NASH Kate Burba
-
- Q&A: ‘Heavy, heartfelt history’ of drug trials for Black patients may fuel NASH disparities Monica Stonehill; Nadege T. Gunn, MD
- Resmetirom achieves ‘meaningful effects’ on NASH resolution, fibrosis stage improvement Monica Stonehill
- UHC shelves prior authorization for GI endoscopy; replacement ‘could be as bad or worse’ Monica Stonehill
- ‘Unfavorable benefit-risk’: FDA panel votes against obeticholic acid approval for NASH Kate Burba